Program
Artesunate
Also written as “Artesunate + Amodiaquine”, “Artesunate ointment” and “Artesunate vaginal insert”.
Its studies are mostly in Malaria · Papillomavirus Infections · Malaria, Falciparum · Cytomegalovirus Infections · Vulvar Diseases, led by 7 companies.
Drug pageArtesunate: every studyMany companies study it; this page follows only the 17 they lead. All 115 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 60 open or running | phase 4since Mar 8, 2007 | Apr 18, 2006 | none ahead |
| Frantz Viral Therapeuticsits history only | 44 open or running | phase 2since Sep 19, 2019 | Sep 19, 2019 | Dec 2026phase 2 · NCT06075264 |
| Metanoic Health | 22 open or running | phase 2since Jul 7, 2025 | Jul 7, 2025 | Jun 30, 2027phase 2 · NCT07095478 |
| Shin Poong Pharmaceuticalits history only | 20 open or running | phase 2since Sep 13, 2018 | Sep 13, 2018 | none ahead |
| Amivasits history only | 11 open or running | phase 2since Feb 25, 2025 | Feb 25, 2025 | May 31, 2028phase 2 · NCT06853184 |
| Pfizerits history only | 10 open or running | phase 1since May 4, 2009 | May 4, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 4since Sep 10, 2009 | Sep 10, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Metanoic Health only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 7, 2025First studies: 2 phase 2 studiesFirst studyNCT07095478, NCT07095309
Ahead
- Jun 30, 2027Primary completion: phase 2 study in CIN 2/3NCT07095478
- Aug 30, 2032Primary completion: phase 2 study in Intestinal NeoplasmsNCT07095309
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Metanoic Health leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07095478CIN 2/3 · Malaysia | 2 | Not yet recruiting | Jun 30, 2027 | 28 |
| NCT07095309Intestinal Neoplasms · Malaysia | 2 | Not yet recruiting | Aug 30, 2032 | 120 |
How it is read
Names in the registry
- “Artesunate”, 6 entries
- “Artesunate + Amodiaquine”, 3 entries
- “Artesunate ointment”, 2 entries
- “Artesunate vaginal insert”, 1 entry
- “Artesunate-amodiaquine”, 1 entry
Conditions, from the studies’ own filings
- Malaria, 7 studies
- Papillomavirus Infections, 3 studies
- Malaria, Falciparum, 2 studies
- Cytomegalovirus Infections, 1 study
- Vulvar Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.